Modulation of Anti-Tumor Immunity and Tumor Microenvironment

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: 30 April 2025 | Viewed by 2434

Special Issue Editor


E-Mail Website
Guest Editor
1. Chief, Department of Biotechnology Medicine, MacKay Memorial Hospital, Taipei, Taiwan
2. Senior Attending Physician, Department of Radiation Oncology, MacKay Memorial Hospital, Taipei, Taiwan
3. Director, Laboratory of Cancer Therapeutics, MacKay Memorial Hospital, Taipei, Taiwan
4. Professor, Department of Artificial Intelligence and Medical Application, MacKay Junior College of Medicine, Nursing and Management, Taipei, Taiwan
5. Professor, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
Interests: cancer immunology; radiation oncology; radiation biology; natural product

Special Issue Information

Dear Colleagues,

In cancer treatment, immunotherapy has demonstrated promising clinical efficacy for the improvement of survival and quality of life. The success of immunotherapy in individual patients greatly depends on the state of anti-tumor immunity and tumor microenvironment. In clinical practice of cancer therapy, the combination of various treatment modalities remains an important strategy, such as the application of immunotherapy, chemotherapy, target therapy, hyperthermia and radiotherapy, etc. However, the impact of various therapeutic modalities on anti-tumor and tumor microenvironments remains to be clarified. It remains a research challenge and an unmet medical need for better understanding alterations of anti-tumor immunity and the tumor microenvironment, especially the influences of various treatment modalities.  Therefore, research on the modulation of anti-tumor and tumor microenvironments using various therapeutic modalities is important for further augmentation of cancer treatment outcomes.

For this Special Issue, we invite you to contribute original research articles, reviews, or shorter perspective articles on all aspects related to the theme of “Modulation of Anti-Tumor Immunity and Tumor Microenvironment". All research regarding basic, translational and clinical studies as well as development of new therapeutic agents or drug repositioning is welcome. Relevant topics include, but are not limited to, the following:

  • Anti-tumor immunity;
  • Tumor microenvironment;
  • Immunotherapy;
  • Chemotherapy;
  • Target therapy;
  • Hyperthermia;
  • Radiotherapy;
  • Novel therapeutic agents;
  • Other treatment modalities.

Dr. Yu-Jen Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anti-tumor immunity
  • tumor microenvironment
  • immunotherapy
  • chemotherapy
  • target therapy
  • hyperthermia
  • radiotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 331 KiB  
Review
The Importance of Predictive Biomarkers and Their Correlation with the Response to Immunotherapy in Solid Tumors—Impact on Clinical Practice
by Raluca Ioana Mihaila, Adelina Silvana Gheorghe, Daniela Luminita Zob and Dana Lucia Stanculeanu
Biomedicines 2024, 12(9), 2146; https://doi.org/10.3390/biomedicines12092146 - 22 Sep 2024
Viewed by 1897
Abstract
Background/Objectives: Immunotherapy has changed the therapeutic approach for various solid tumors, especially lung tumors, malignant melanoma, renal and urogenital carcinomas, demonstrating significant antitumor activity, with tolerable safety profiles and durable responses. However, not all patients benefit from immunotherapy, underscoring the need for [...] Read more.
Background/Objectives: Immunotherapy has changed the therapeutic approach for various solid tumors, especially lung tumors, malignant melanoma, renal and urogenital carcinomas, demonstrating significant antitumor activity, with tolerable safety profiles and durable responses. However, not all patients benefit from immunotherapy, underscoring the need for predictive biomarkers that can identify those most likely to respond to treatment. Methods: The integration of predictive biomarkers into clinical practice for immune checkpoint inhibitors (ICI) holds great promise for personalized cancer treatment. Programmed death ligand 1 (PD-L1) expression, tumor mutational burden (TMB), microsatellite instability (MSI), gene expression profiles and circulating tumor DNA (ctDNA) have shown potential in predicting ICI responses across various cancers. Results: Challenges such as standardization, validation, regulatory approval, and cost-effectiveness must be addressed to realize their full potential. Predictive biomarkers are crucial for optimizing the clinical use of ICIs in cancer therapy. Conclusions: While significant progress has been made, further research and collaboration among clinicians, researchers, and regulatory institutes are essential to overcome the challenges of clinical implementation. However, little is known about the relationship between local and systemic immune responses and the correlation with response to oncological therapies and patient survival. Full article
(This article belongs to the Special Issue Modulation of Anti-Tumor Immunity and Tumor Microenvironment)
Back to TopTop